Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...

BMO Capital says Biogen (BIIB) is looking for an early potential deal by offering to buy Sage Therapeutics (SAGE) for $7.22 per share. Such an offer reflects Biogen’s interest in reducing its ...

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an unsolicited, nonbinding proposal to ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...